Botox OK'd by US FDA to treat overactive bladder
(REUTERS) - The popular Botox wrinkle treatment made by Allergan Inc has been approved to treat adults with overactive bladder who cannot tolerate or failed to be helped by other drugs for the condition, the United States (US) Food and Drug Administration (FDA) said on Friday.
Botox injected into the bladder muscle causes the bladder to relax, increasing its storage capacity and reducing episodes of urinary incontinence, or leakage.
"Clinical studies have demonstrated Botox's ability to significantly reduce the frequency of urinary incontinence," Mr Hylton Joffe, director of the FDA's Division of Reproductive and Urologic Products, said in a statement. "Today's approval provides an important additional treatment option for patients with overactive bladder, a condition that affects an estimated 33 million men and women in the United States."
Botox had previously been approved for other non-cosmetic uses, such as migraine headaches, severe underarm sweating and loss of bladder control due to nerve damage.